Neo-NTP-CRT for Locally Advanced ESCC

Summary

The investigators hypothesize that nivolumab combined with neoadjuvant chemoradiotherapy (CRT) is safe and effective in patients with locally advanced esophageal squamous cell carcinoma (LAESCC).

Timeline

Start

2021-02-22

Primary completion

2023-03-01

Completion

2024-03-01

Outcome

Missed primary endpoint

paper Fourteen patients received esophagectomy, with pCR achieved in 4, below the criterion for continuing to stage II. PMID 41862680 ↗

Publications

• Huang TC, Guo JC, Lin CC, Kuo HY, Chuang CH, Cheng JC, Hsu FM, Lee JM, Huang PM, Liang CW, Li YI, Hsu CH. Neoadjuvant immunochemoradiotherapy with nivolumab, paclitaxel, and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma. Br J Cancer. 2026 May;134(10):1403-1412. doi: 10.1038/s41416-026-03349-6. Epub 2026 Mar 20.

Drugs

Indications